Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zecotek and Fujikura sign distribution agreement
In order to finalize the structural and operational details, both parties have agreed to extend the current letter of intent to January 31, 2008. Under the proposed agreement
In order to finalize the structural and operational details, both parties have agreed to extend the current letter of intent to January 31, 2008. Under the proposed agreement
The company said that shipment of these products has commenced. As the first company to file an abbreviated new drug application (ANDA) with a Paragraph IV patent certification
Pursuant to the definitive acquisition agreement, Arura has acquired all of the outstanding securities from the securities holders of Silkit for an aggregate base purchase price of CAD1
Shire expects the three additional dosage strengths of 20mg, 40mg and 60mg will be available in retail pharmacies in the second quarter of 2008 to supplement the existing
These studies will enroll in excess of 2,400 patients recruited globally. The GW642444 long-acting beta agonist (LABA) Phase IIb dose-optimization study will enroll approximately 600 patients with persistent
The FDA grants orphan designation to products that are intended to address diseases affecting fewer than 200,000 persons in the US. If oral fludarabine receives FDA approval, this
The Master-VU System consists of a B-scan probe that can be interfaced to a standard personal computer (via a USB cable connection) using Sonomed’s proprietary software, thereby converting
Patients who have completed the six months trial were provided the opportunity to continue treatment with ISA247 as part of an extension to the initial trial. This six-month
According to BenOra, this acquisition will allow the company to accelerate the goal of bringing state-of-the-art technology to a larger patient population in central Arizona. Solis Women’s Health
The court has denied Pfizer’s request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of Pfizer’s enantiomer (calcium salt) patent in July